Impact of roxadustat on anemia management in infected patients undergoing long-term dialysis: a retrospective cohort analysis.

ABSTRACT:

Introduction

The efficacy of oral roxadustat in dialysis patients with renal anemia and overt infections remains uncertain.

Objectives

In this retrospective cohort study, 2816 such patients were screened, of whom 167 were enrolled and assigned to either roxadustat (n = 88) or recombinant human EPO (rHuEPO; n = 79) for treatment.

Methods and results

Baseline hemoglobin levels were 90.3 ± 15.2 g/L and 91.9 ± 17.8 g/L, respectively. All patients received a mean of 10.6 ± 3.3 days of infection treatment. Types of infection included pulmonary, peritoneal dialysis-associated peritonitis, catheterrelated, urinary tract, and others. Compared with rHuEPO, roxadustat led to significantly greater increases in hemoglobin and ΔHb, and more pronounced improvements in ferritin, tran

SUBMITTER: Wang L 

PROVIDER: S-EPMC12540434 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature